DBVT 最新10-Q变化
将 DBVT 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-28 与上一份 10-Q · 2026-07-16
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +63 | −43 | ~11 | 10 |
| 市场风险(第3项) | 文字有新增/删除 | +3 | −1 | ~8 | 16 |
| 控制与程序 | 文字有新增/删除 | +3 | −1 | ~8 | 16 |
| 法律诉讼 | 文字有新增/删除 | +3 | −1 | ~8 | 16 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +3 | −1 | ~8 | 16 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-28
Our most advanced product candidate is Viaskin Peanut patch, evaluated as a potential immunotherapy for children with peanut allergy in twelve clinical trials, including four Phase 2 trials and five completed Phase 3 trials. We are advancing two separate Viaskin Peanut product candidates in parallel…
During the third quarter of 2026, we made significant progress toward the potential commercialization of VIASKIN® Peanut. Following extensive interactions with the FDA during the quarter, we submitted our BLA for VIASKIN Peanut in children ages 4 through 7 years old on September 29, 2026 and request…
In parallel, supported by our strengthened financial resources extended through the refresh of the ATM Program, we accelerated the build-out of our commercial capabilities and continued to advance clinical development, manufacturing and supply-chain readiness and institutional investor engagement, i…
We are actively working to advance launch infrastructure, including distribution and patient access capabilities to support the launch of VIASKIN Peanut patch in the United States, upon approval..
Submission of BLA FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
相对上期删除的文字 · 来源:10-Q · 2026-07-16
Our most advanced product candidate is Viaskin Peanut patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials. The Company is planning for a BLA submission in the thir…
During the second quarter of 2026, the Company continued to advance the key elements supporting the potential commercialization of VIASKIN® Peanut, including regulatory readiness, clinical development, manufacturing and supply-chain preparedness, commercial launch planning and institutional investor…
BLA Submission Update for VIASKIN® Peanut Patch for children aged 4 through7 years
On June 29, 2026, the Company announced that it has had ongoing detailed iterative engagement with FDA with the goal of ensuring a complete, efficient, and timely review of the Company’s BLA for children aged 4 through 7 years, and, through this process and based on FDA review, DBV received valuable…
On June 2, 2026, the Company announced that the first participant had been screened in the Phase 2 THRIVE study evaluating the efficacy and safety of the VIASKIN® Peanut patch in infants aged 6 through 12 months with peanut allergy. THRIVE is a single-arm, open-label study designed to assess the abi…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-10-28
•our expectations regarding initiation of the confirmatory effectiveness study for VIASKIN Peanut patch in 1 - 3 year olds;
•anticipated support for the BLA review for VIASKIN Peanut patch in 4 - 7 year olds;
•our expectations with respect to the grant of Priority Review designation by FDA for BLA for VIASKIN Peanut patch in 4 - 7 year olds;
相对上期删除的文字 · 来源:10-Q · 2026-07-16
•anticipated support for the BLA re-submission for VIASKIN Peanut patch to FDA;
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-10-28
•our expectations regarding initiation of the confirmatory effectiveness study for VIASKIN Peanut patch in 1 - 3 year olds;
•anticipated support for the BLA review for VIASKIN Peanut patch in 4 - 7 year olds;
•our expectations with respect to the grant of Priority Review designation by FDA for BLA for VIASKIN Peanut patch in 4 - 7 year olds;
相对上期删除的文字 · 来源:10-Q · 2026-07-16
•anticipated support for the BLA re-submission for VIASKIN Peanut patch to FDA;
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-10-28
•our expectations regarding initiation of the confirmatory effectiveness study for VIASKIN Peanut patch in 1 - 3 year olds;
•anticipated support for the BLA review for VIASKIN Peanut patch in 4 - 7 year olds;
•our expectations with respect to the grant of Priority Review designation by FDA for BLA for VIASKIN Peanut patch in 4 - 7 year olds;
相对上期删除的文字 · 来源:10-Q · 2026-07-16
•anticipated support for the BLA re-submission for VIASKIN Peanut patch to FDA;
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-10-28
•our expectations regarding initiation of the confirmatory effectiveness study for VIASKIN Peanut patch in 1 - 3 year olds;
•anticipated support for the BLA review for VIASKIN Peanut patch in 4 - 7 year olds;
•our expectations with respect to the grant of Priority Review designation by FDA for BLA for VIASKIN Peanut patch in 4 - 7 year olds;
相对上期删除的文字 · 来源:10-Q · 2026-07-16
•anticipated support for the BLA re-submission for VIASKIN Peanut patch to FDA;
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议